Medication Assisted Treatment For Opioid Use Disorder

Timothy W. Fong, MD
Professor of Psychiatry
UCLA Addiction Psychiatry
LA SBIRT Network
April 29, 2017
Disclosure of Relevant Financial Relationships

<table>
<thead>
<tr>
<th>Name</th>
<th>Commercial Interests</th>
<th>Relevant Financial Relationships: What Was Received</th>
<th>Relevant Financial Relationships: For What Role</th>
<th>No Relevant Financial Relationships with Any Commercial Interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indivior</td>
<td>Honorarium</td>
<td></td>
<td>Speaker's Bureau</td>
<td></td>
</tr>
<tr>
<td>Constellation Health</td>
<td>Research Grant</td>
<td></td>
<td>Research</td>
<td></td>
</tr>
</tbody>
</table>
Objectives

1. Describe the mechanisms, side effects, and treatment goals of FDA-approved medications for opioid use disorder

2. Discuss at least two advantages and disadvantages of employing medicines in a recovery treatment program

3. Explain at least three administrative protocols and processes that are required to implement medication-assisted treatment into a variety of healthcare settings.
What is Medication Assisted Treatment (MAT)?

• MAT is the use of FDA-approved medications, in combination with counseling and behavioral therapies, to provide a whole-person approach to the treatment of addictive disorders.

• Research shows that medication and behavioral therapies works best!

• MAT is clinically driven with a focus on individualized client care.
SAMHSA TIP for MAT

Medication-Assisted Treatment
For Opioid Addiction in Opioid Treatment Programs

A Treatment Improvement Protocol

TIP 43
Key Components to MAT

1) pharmacological therapy
2) psychosocial services
3) integration of care
4) education and outreach
Expectations of Medications

- Manage detoxification
- Target urges / cravings
- Increase likelihood of abstinence
- Reduce harm from addictive behavior
- Lay the groundwork to do recovery
History of MAT

- 1972: Methadone approved
- 1980s: War on Drugs
- 1990s: “Addiction as a brain disease”
  - Advances in genetic, neuroimaging, animal models, slow medication development
- 2000s: Buprenorphine approved
- 2010s: Steadier Growth of Meds
History of Physicians and MAT

• 1990-2000
  – MDs had limited choices, trainings to prescribe MAT from office-based settings

• 2000 – present
  – DATA 2000 opens doors but capacity low
  – Addiction Psychiatrists
  – Addition Medicine (FP, IM)
  – MDs usually separated from SUD/MH providers
My Own Experience With MAT

• 1998: Graduate Medical School
• 2002: Graduate Residency
• 2003: Complete Addiction Fellowship
• 2004: Obtain “Bup Waiver”
• 2004 – Present: Office-based MAT
Overarching Principle of MAT

“Drugs are substances that change body’s functioning. Medications are drugs that restore normal functioning”
MAT Advantages

- Uses power of science to improve treatment outcomes
- Uses biopsychosocial approach
- Improve treatment retention
- Target symptoms that were previously not reachable by counseling / therapy
MAT Disadvantages

• “Magic Pills”
• May de-emphasize recovery process
  – Home, health, purpose, community
• Expensive, time consuming
• Long-term impact not fully known
• Deepens the “generational gap” among those in recovery
Recovery

• “A voluntarily maintained lifestyle characterized by sobriety, personal health and citizenship”

• J. Substance Abuse Treatment 2008
What are the FDA-approved medications for opioid use disorders?
FDA-Approved Medications for OUD

<table>
<thead>
<tr>
<th>Opioid Use Disorder</th>
<th>Generic Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial Agonist</td>
<td>Buprenorphine/Naloxone (sl)</td>
</tr>
<tr>
<td></td>
<td>Buprenorphine (sl)</td>
</tr>
<tr>
<td></td>
<td>Buprenorphine (implant)</td>
</tr>
<tr>
<td>Full Agonists</td>
<td>Methadone (liquid)</td>
</tr>
<tr>
<td>Antagonists</td>
<td>Naltrexone (oral)</td>
</tr>
<tr>
<td></td>
<td>Naltrexone (monthly injection)</td>
</tr>
</tbody>
</table>
Buprenorphine
How it Works

• Office-based treatment
• Physicians prescribing must have certification from DEA (100 pt. Limit)
• Manages withdrawal
• Used as a maintenance therapy
• Limited abuse potential
Pharmacology

- Semi-synthetic morphine alkaloid
- Partial agonist at mu receptor
  - Ceiling effects
- Antagonist at kappa receptor
- Schedule III
- Over 20 years of research
Full vs. Partial Agonist

% Receptor Activity vs. Dose

- Full Agonist:
  - Overdose
  - Intoxication
- Partial Agonist:
  - Withdrawal
Buprenorphine/Naloxone Tablets

2mg/0.5mg

8mg/2mg
# SUBOXONE Film

<table>
<thead>
<tr>
<th>Strength</th>
<th>Composition</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2 mg</strong></td>
<td>buprenorphine/0.5 mg naloxone</td>
<td><img src="image1.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>4 mg</strong></td>
<td>buprenorphine/1 mg naloxone</td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>8 mg</strong></td>
<td>buprenorphine/2 mg naloxone</td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td><strong>12 mg</strong></td>
<td>buprenorphine/3 mg naloxone</td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
</tbody>
</table>

For complete Prescribing Information, visit suboxone.com.

SUBOXONE® Sublingual Film is a registered trademark of Reckitt Benckiser (UK) Ltd.
Zubsolv Sublingual Tablets

Available doses (BUP/NX): 1.4 mg / 0.36 mg; 5.7 mg / 1.4 mg

Recommended maintenance dose: 11.4 mg / 2.8 mg
Bunavail Buccal Film

Available dosages (BUP/NX):  2.1 mg / 0.3 mg; 4.2 mg/0.7 mg; 6.3 mg/ 1.0mg

Recommended maintenance dose: 8.4mg / 1.4mg
Buprenorphine, Methadone, LAAM: Treatment Retention

Percent Retained

Study Week

Buprenorphine: Retention and Mortality

All Patients received group CBT Relapse Prevention, Weekly Individual Counseling, 3x Weekly Urine Screens. n=20 per group

4 deaths

0 deaths

Kakko J, Lancet 2003
Most often heard quotes with Buprenorphine

“Doc, I feel normal”
“I wake up not sick”
“I have my life back”

• Treatment in normal medical settings:
  – Encourages continuity of medical/specialty care
  – Encourages relationship building with clinicians
  – Legitimize opioid dependence as a normal, treatable, chronic illness
Naltrexone

Revia® or Depade®
Opioid Antagonist: Naltrexone

Opioid Blockade
FDA Approved for Alcohol and Opioid Use Disorder
Prevents relapse
Strong Anti-Craving
Minimized overdose risk; especially after detox
Naltrexone

- **Oral:** 50 mg tablet
- **Injectable:** 380 mg IM every four weeks
- **Implants:** NOT FDA-approved
Extended-Release Naltrexone

**Dosing:**
- 380mg injection in deep gluteal muscle every 4 weeks
- Must be administered by a healthcare professional and should alternate sides each month.
- Blocks opioid receptors for *one entire month* compared to approximately 28 doses of oral naltrexone.

It is **not possible to remove** it from the body once extended-release naltrexone has been injected. Large doses of opioids may be required to override the blockade in a medically monitored setting.
Injectable NTX Provides a Sustained-Release of Medication

IM Naltrexone Eliminates Daily Adherence Decisions¹

• Naltrexone utilizes a delivery system that
  – Provides a month of medication in a single dose

• Adherence to any treatment program is essential for successful outcomes

• Administration by a healthcare provider ensures that the patient receives the medication as directed

“…addressing patient adherence systematically will maximize the effectiveness of these medications.”²

–Updated NIAAA Clinician’s Guide

2. NIAAA. 2007. NIH publication 07-3769.
Research About Extended-Release Naltrexone for Opioid Use Disorder

When compared to placebo, those receiving extended release naltrexone for 6 months:

- Had fewer opioid positive urines
- Stayed in treatment longer (improved retention)
- Had fewer cravings
- Showed greater improvement in the mental component of quality of life and overall health status
- Generally tolerated the medication without significant adverse effects

Krupitsky, et al., 2010
Importantly, there were no attempts to override the blockade with large doses of opioids.

No accidental or intentional overdoses during or post-treatment.

No increase in rates of non-opioid drug use—Consistent with other studies demonstrating reduced use of other drugs when heroin use declined.

Comer et al., 2006
Methadone
Methadone

- Alleviates opioid withdrawal and craving (without intoxication)
- Used for opioid detoxification or maintenance therapy; also used as analgesic.
- Also known under brand names:
  - Methadose®
  - Dolophine®
- FDA approved in 1964
Methadone: Clinical Properties

- Orally active synthetic μ agonist
- Action: CNS depressant/ analgesic
- Long half-life, slow elimination
- Effects last 24 hours
- Once daily dosing maintains constant blood level
- Prevents withdrawal, reduces craving and use
- Facilitates rehabilitation
- Clinic dispensing limits availability
Blood levels: methadone vs. short-acting opioids

- *Heroin, Opioid painkillers*
- *Methadone*

<table>
<thead>
<tr>
<th>Time</th>
<th>Serum level</th>
</tr>
</thead>
<tbody>
<tr>
<td>8AM</td>
<td></td>
</tr>
<tr>
<td>Noon</td>
<td></td>
</tr>
<tr>
<td>4PM</td>
<td></td>
</tr>
<tr>
<td>8PM</td>
<td></td>
</tr>
<tr>
<td>MN</td>
<td></td>
</tr>
<tr>
<td>4AM</td>
<td></td>
</tr>
<tr>
<td>8AM</td>
<td></td>
</tr>
</tbody>
</table>
Treatment Outcome Data: Methadone

- 8-10 fold reduction in death rate
- Reduction in drug use
- Reduction in criminal activity
- Increased treatment retention
- Engagement in socially productive roles; improved family and social function
- Increased employment
- Improved physical and mental health
- Reduced spread of infectious disease/HIV
Methadone Maintenance: Disadvantages

- Withdrawal from methadone can be difficult
- Clinic dispensing: daily travel and time commitment
- Variable duration of action
- Diversion
- Stigma
Probuphine Implant
Probuphine

• Recently FDA Approved
• Implantable formulation of buprenorphine HCL (80 mg) for the treatment of opioid dependence following clinical stability on low to moderate doses of sublingual buprenorphine (8mg/day or less)
• Probuphine is inserted subdermally into the inner side of the upper arm in a brief in-office procedure under local anesthetic, and provides sustained release of buprenorphine for 6 months
  – At the end of each 6-month period, Probuphine is removed in a brief, in-office procedure
Overdose Education and Naloxone Distribution (OEND)

• ~20,000 deaths / yr
• Naloxone (injectable and nasal spray)
  – Reverses opiate overdoses
• In early 2015, California law allows pharmacists to distribute naloxone directly to patients
How to identify an opioid overdose:

Look for these common signs:
- The person won’t wake up even if you shake them or say their name
- Breathing slows or even stops
- Lips and fingernails turn blue or gray
- Skin gets pale, clammy

In case of overdose:

1. Call 911 and give naloxone
   If no reaction in 3 minutes, give second naloxone dose
2. Do rescue breathing or chest compressions
   Follow 911 dispatcher instructions
3. After naloxone
   Stay with person for at least 3 hours or until help arrives

How to give naloxone:
There are 3 ways to give naloxone. Follow the instructions for the type you have.

Nasal spray naloxone

1. Take off yellow caps.
2. Screw on white cone.
3. Take purple cap off capsule of naloxone.
4. Gently screw capsule of naloxone into barrel of syringe.
5. Insert white cone into nostril; give a short, strong push on end of capsule to spray naloxone into nose: **ONE HALF OF THE CAPSULE INTO EACH NOSTRIL.**
6. If no reaction in 3 minutes, give second dose.

Injectable naloxone

1. Remove cap from naloxone vial and uncover the needle.
2. Insert needle through rubber plug with vial upside down. Pull back on plunger and take up 1 ml.
3. Inject 1 ml of naloxone into an upper arm or thigh muscle.
4. If no reaction in 3 minutes, give second dose.

Auto-injector

The naloxone auto-injector is FDA approved for use by anyone in the community. It contains a speaker that provides instructions to inject naloxone into the outer thigh, through clothing if needed.
Naloxone Formulations

Generic
Injection Solution: 0.4 MG/1 ML, 1 MG/1 ML

Evzio
Injection Solution: 0.4 MG/0.4 ML

Narcan
Nasal Spray: 4 MG/0.1 ML
Essential Questions of MAT
 Aren’t I just substituting one drug for another?
Isn’t it better for me to be in recovery without medications?
How long do I need to take medication? Could this be life-long?
My sponsor got sober without medications, so why can’t I?
Our treatment program will never accept MAT.
What MAT looks like at UCLA

• Outpatient offices
• Appointments 3 days a week
• Patients / families call
  – 1 week up to 6 week waitlist for appointment
• Must have insurance or ability to self-pay
What MAT looks like at UCLA

• Intake: 60 min with MD
  – Laboratory studies available on site
• Monthly visits (with frequent communications)
• Therapy off-site, usually
• 12-step highly recommended
• Solo Practice, for all intents and purposes
What MAT looks Like at UCLA

- Electronic records
- Electronic prescriptions
- Paper prescriptions for buprenorphine
- Follow-up visits: 30 min
- Insurance haggling often occurs
  Prior Authorizations, Visits,
Implementing MAT
Implementing MAT

• Many different, empirically tested models of delivery
  – Differs based on staffing, space, provider capacity, payment structures, program philosophies, etc.

• No ONE model is “the best way” of delivering MAT
General Policies of MAT Delivery

- in accordance with Good Clinical Practice Guideline for each medication;
- under the supervision of a medical professional working within his/her scope of practice;
- as part of a comprehensive package of services combining the use of medication with counseling, behavioral therapies and other supportive services must be delivered simultaneously. MAT NEVER IN ISOLATION.
Principles for Implementation

- Licensed prescribers operating within their scope of practice assist the client in clinical decision-making, assuring awareness of all appropriate therapeutic alternatives.
- Informed consent for all pharmacotherapies must be obtained, including discussion about the advantages and disadvantages of MAT, taking into consideration the benefits, side effects, alternatives, cost, availability, and potential for diversion.
Review MAT Policies

- Policies are reviewed at least annually to ensure
- a) consistency with current practice standards in behavioral health care and
- b) compliance with federal, state, and county regulations, licensure requirements and accreditation standards.
Recent Major Review of MAT

The MAT models of care that were viewed as particularly successful utilized a designated non-physician staff member in the integration/coordination role.
Improving MAT Implementation and Outcome

• Education and outreach critical for reducing stigma associated with MAT,
• increasing the pool of prescribing physicians, and increasing uptake, particularly in settings in which stigma is still high.
• Education was also viewed as critical for improving standards and quality of care.
Challenges to MAT

- including methods for measuring quality of care,
- how to assess patients to better individualize care, optimal psychosocial components of
- MAT, effectiveness of mid-level prescribing, enhancing access to and uptake of MAT in primary care settings,
- effectiveness of newer or alternative medications for OUD
Challenges to MAT

- medications dosing strategies, cost and cost-effectiveness, methods for reducing diversion,
- effective implementation methods, optimal methods for coordination and integration of care
- effectiveness of telemedicine approaches
Further Resources

- SAMHSA Treatment Locator
  - http://findtreatment.samhsa.gov
  - 1-800-662-HELP
- PCSS – O; PCSS-MAT
- American Academy of Addiction Psychiatry
- American Society of Addiction Medicine
ASAM developed the National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use to provide information on evidence-based treatment of opioid use disorder.
PCSS - MAT

• PCSS-MAT Mentor Program is designed to offer general information to clinicians about evidence-based clinical practices in prescribing medications for opioid addiction.

• PCSS-MAT Mentors comprise a national network of trained providers with expertise in medication-assisted treatment, addictions and clinical education.

• pcssmat.org/mentoring
Providers’ Clinical Support System
For Medication Assisted Treatment

What We Do
We are a national training and mentoring project developed in response to the prescription opioid misuse epidemic and the availability of pharmacotherapies to address opioid use disorder. The overarching goal of PCSS-MAT is to make available the most effective medication-assisted treatments to serve patients in a variety of settings, including primary care, psychiatric care, substance use disorder treatment, and pain management settings.

NP and PA Information on MAT Waiver Training
If you are a Nurse Practitioner or Physician Assistant interested in completing the required 24 hours of training for your MAT waiver training, you may take the 8-hour waiver training immediately. NOTE: The remaining 16 hours of training have been developed and are under review for CE accreditation. We anticipate these courses to be available in early 2017.
AAAP Annual Meeting 2017
December

Rancho Bernardo Inn, San Diego, CA
December 7-10, 2017

The Annual Meeting and Scientific Symposium provides the latest scientific developments in Addiction Psychiatry for physicians and allied health professionals who treat patients with...
Obama Administration Announces Additional Actions to Address the Prescription Opioid Abuse and Heroin Epidemic

March 28, 2016
Action List: “Turn the Tide”

- Expand access to treatment
- Create MH/SUD Taskforce
- Prevent Overdose Deaths (naloxone)
- SUD Treatment Parity
- Implement Syringe Services Programs
- Medical Schools – Mandated Prescriber Education
Contact Information
Timothy Fong MD
UCLA Addiction Medicine Clinic
310-825-9989 (appts)
310-825-1479 (office)
tfong@mednet.ucla.edu
uclagamblingprogram.org